ctDNA guides anti-EGFR rechallenge.

doi:10.1038/s41571-022-00681-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ctDNA guides anti-EGFR rechallenge.

Nature reviews. Clinical oncology - 1 Oct 2022

Sidaway Peter

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to ErbB Receptors
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 36008478
DOI: 10.1038/s41571-022-00681-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ctDNA guides anti-EGFR rechallenge.PMID 36008478Read ↗

Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC.Semantic proximity Read ↗

EGFR testing in lung cancer is ready for prime time.Semantic proximity Read ↗

EGFR pharmacogenomics: the story continues to mutate and evolve.Semantic proximity Read ↗

The regulatory landscape for actively personalized cancer immunotherapiesSemantic proximity Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

RET-oncogene-targeting drugs draw notice.Semantic proximity Read ↗

FGFR-TACC approaches the first turn in the race for targetable GBM mutations.Semantic proximity Read ↗

Kidney cancer: Tracking and therapy selection using ctDNA.Semantic proximity Read ↗

Targeting APOBECs in cancer: It’s about timingSemantic proximity Read ↗

Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease.Semantic proximity Read ↗

Cell-free DNA as a post-treatment surveillance strategy: current statusSemantic proximity Read ↗

Achieving personalized cancer medicine: trials and tribulations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.